WALTHAM, Mass.--(BUSINESS WIRE)--
BG Medicine (NASDAQ: BGMD) today announced the pricing of its initial
public offering of 5,000,000 shares of its common stock at a price of
$7.00 per share, before underwriting discounts and commissions. All
shares are being sold by the Company. The shares are expected to begin
trading today on the NASDAQ Global Market under the ticker symbol
"BGMD." In addition, the underwriters have been granted a 30-day option
to purchase up to an additional 750,000 shares of common stock at the
initial public offering price, less underwriting discounts and
commissions, to cover over-allotments, if any.
Lazard Capital Markets LLC is acting as the sole bookrunning manager for
the initial public offering, and Baird and Cowen and Company are acting
A registration statement relating to this offering was declared
effective by the Securities and Exchange Commission on February 3, 2011.
This offering is being made solely by means of a written prospectus, a
copy of which may be obtained from Lazard Capital Markets LLC by mail at
30 Rockefeller Plaza, 60th Floor, New York, NY 10020, Attention:
Syndicate Department, or by calling toll-free (800) 542-0970.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of these
securities in any state or jurisdiction in which such an offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
About BG Medicine
BG Medicine is a life sciences company focused on the discovery,
development, and commercialization of novel diagnostics based on
biomarkers to improve patient outcomes and contain healthcare costs.
Michael W. Rogers, 781-890-1199
EVP & Chief
Source: BG Medicine
News Provided by Acquire Media